Title: Olav Benjamin Ryan - Innovator in Radiopharmaceuticals
Introduction
Olav Benjamin Ryan is an inventor based in Oslo, Norway. He is currently employed at Bayer AS, where he focuses on the development of innovative radiopharmaceuticals. Despite having no granted patents to his name, Ryan is actively engaged in research and development, contributing to advancements in medical technology.
Latest Patent Applications
Ryan's latest patent applications include two significant innovations in the field of radiopharmaceuticals. The first application describes a tissue-targeting complex that comprises a tissue targeting moiety and an octadentate hydroxypyridinone-containing ligand. This complex includes four HOPO moieties and the ion of an alpha-emitting thorium radionuclide. Notably, at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group, and the tissue targeting moiety has binding affinity for the CD33 receptor. The application also outlines a corresponding pharmaceutical formulation and methods of use in treatment, as well as methods of manufacture.
The second application similarly details a tissue-targeting complex, but this one has binding affinity for the CD22 receptor. It also provides methods of treatment utilizing such complexes and methods of formation of these complexes.
Conclusion
Olav Benjamin Ryan is a promising inventor in the field of radiopharmaceuticals, actively working on innovative solutions that could enhance medical treatments. His contributions, although not yet patented, reflect a commitment to advancing healthcare technology.